Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention

Stig Lyngbæk; Jacob L Marott; Daniél V Møller; Michael Christiansen; Kasper K Iversen; Peter M Clemmensen; Jesper Eugen-Olsen; Jørgen Jeppesen; Peter R Hansen

doi:10.1016/j.amjcard.2012.08.008

Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention

Stig Lyngbæk, Jacob L Marott, Daniél V Møller, Michael Christiansen, Kasper K Iversen, Peter M Clemmensen, Jesper Eugen-Olsen, Jørgen Jeppesen, Peter R Hansen

53 Citations (Scopus)

Abstract

The plasma level of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is an independent predictor of cardiovascular disease and all-cause mortality in healthy subjects. The prognostic capability of suPAR, its temporal course, and its relation to plasma C-reactive protein (CRP) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention (PCI) is unknown. Therefore, the plasma suPAR and CRP levels were measured in 296 consecutive patients with ST-segment elevation myocardial infarction admitted for primary PCI at baseline and every 6 to 8 hours thereafter until the cardiac biomarker levels had peaked. The end points were all-cause mortality and fatal or nonfatal recurrent myocardial infarction (MI). During a median follow-up period of 5.75 years, 69 deaths and 48 nonfatal and 14 fatal recurrent MIs occurred. All-cause mortality increased significantly from 8.1% to 41.5% across increasing quartiles of suPAR levels at the end of follow-up (log-rank p

Original language	English
Journal	American Journal of Cardiology
Volume	110
Issue number	12
Pages (from-to)	1756-63
Number of pages	8
ISSN	0002-9149
DOIs	https://doi.org/10.1016/j.amjcard.2012.08.008
Publication status	Published - 15 Dec 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.amjcard.2012.08.008

Fingerprint

Dive into the research topics of 'Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention'. Together they form a unique fingerprint.

Cite this

Lyngbæk, S., Marott, J. L., Møller, D. V., Christiansen, M., Iversen, K. K., Clemmensen, P. M., Eugen-Olsen, J., Jeppesen, J., & Hansen, P. R. (2012). Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention. American Journal of Cardiology, 110(12), 1756-63. https://doi.org/10.1016/j.amjcard.2012.08.008

Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention. / Lyngbæk, Stig; Marott, Jacob L; Møller, Daniél V et al.

In: American Journal of Cardiology, Vol. 110, No. 12, 15.12.2012, p. 1756-63.

Research output: Contribution to journal › Journal article › Research › peer-review

Lyngbæk, S, Marott, JL, Møller, DV, Christiansen, M, Iversen, KK, Clemmensen, PM, Eugen-Olsen, J, Jeppesen, J & Hansen, PR 2012, 'Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention', American Journal of Cardiology, vol. 110, no. 12, pp. 1756-63. https://doi.org/10.1016/j.amjcard.2012.08.008

Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM et al. Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention. American Journal of Cardiology. 2012 Dec 15;110(12):1756-63. doi: 10.1016/j.amjcard.2012.08.008

@article{e1eb1da27bfd4d17b5d4cc8cb7afa607,

title = "Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention",

abstract = "The plasma level of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is an independent predictor of cardiovascular disease and all-cause mortality in healthy subjects. The prognostic capability of suPAR, its temporal course, and its relation to plasma C-reactive protein (CRP) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention (PCI) is unknown. Therefore, the plasma suPAR and CRP levels were measured in 296 consecutive patients with ST-segment elevation myocardial infarction admitted for primary PCI at baseline and every 6 to 8 hours thereafter until the cardiac biomarker levels had peaked. The end points were all-cause mortality and fatal or nonfatal recurrent myocardial infarction (MI). During a median follow-up period of 5.75 years, 69 deaths and 48 nonfatal and 14 fatal recurrent MIs occurred. All-cause mortality increased significantly from 8.1% to 41.5% across increasing quartiles of suPAR levels at the end of follow-up (log-rank p",

author = "Stig Lyngb{\ae}k and Marott, {Jacob L} and M{\o}ller, {Dani{\'e}l V} and Michael Christiansen and Iversen, {Kasper K} and Clemmensen, {Peter M} and Jesper Eugen-Olsen and J{\o}rgen Jeppesen and Hansen, {Peter R}",

year = "2012",

month = dec,

day = "15",

doi = "10.1016/j.amjcard.2012.08.008",

language = "English",

volume = "110",

pages = "1756--63",

journal = "Am. J. Cardiol.",

issn = "0002-9149",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention

AU - Lyngbæk, Stig

AU - Marott, Jacob L

AU - Møller, Daniél V

AU - Christiansen, Michael

AU - Iversen, Kasper K

AU - Clemmensen, Peter M

AU - Eugen-Olsen, Jesper

AU - Jeppesen, Jørgen

AU - Hansen, Peter R

PY - 2012/12/15

Y1 - 2012/12/15

N2 - The plasma level of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is an independent predictor of cardiovascular disease and all-cause mortality in healthy subjects. The prognostic capability of suPAR, its temporal course, and its relation to plasma C-reactive protein (CRP) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention (PCI) is unknown. Therefore, the plasma suPAR and CRP levels were measured in 296 consecutive patients with ST-segment elevation myocardial infarction admitted for primary PCI at baseline and every 6 to 8 hours thereafter until the cardiac biomarker levels had peaked. The end points were all-cause mortality and fatal or nonfatal recurrent myocardial infarction (MI). During a median follow-up period of 5.75 years, 69 deaths and 48 nonfatal and 14 fatal recurrent MIs occurred. All-cause mortality increased significantly from 8.1% to 41.5% across increasing quartiles of suPAR levels at the end of follow-up (log-rank p

AB - The plasma level of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is an independent predictor of cardiovascular disease and all-cause mortality in healthy subjects. The prognostic capability of suPAR, its temporal course, and its relation to plasma C-reactive protein (CRP) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention (PCI) is unknown. Therefore, the plasma suPAR and CRP levels were measured in 296 consecutive patients with ST-segment elevation myocardial infarction admitted for primary PCI at baseline and every 6 to 8 hours thereafter until the cardiac biomarker levels had peaked. The end points were all-cause mortality and fatal or nonfatal recurrent myocardial infarction (MI). During a median follow-up period of 5.75 years, 69 deaths and 48 nonfatal and 14 fatal recurrent MIs occurred. All-cause mortality increased significantly from 8.1% to 41.5% across increasing quartiles of suPAR levels at the end of follow-up (log-rank p

U2 - 10.1016/j.amjcard.2012.08.008

DO - 10.1016/j.amjcard.2012.08.008

M3 - Journal article

C2 - 22981263

SN - 0002-9149

VL - 110

SP - 1756

EP - 1763

JO - Am. J. Cardiol.

JF - Am. J. Cardiol.

IS - 12

ER -